Polaris initiates Phase I prostate cancer trial
Polaris has initiated Phase I trial evaluating its cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in combination with docetaxel in advanced solid tumors with emphasis on prostate cancer patients.
In the combination trial, patients will receive weekly intramuscular injections of ADI-PEG 20 until disease progression.
The primary endpoints of the study are safety and efficacy, and secondary endpoints will include finding the maximum tolerated dose of ADI-PEG 20 with docetaxel.
Docetaxel is currently approved for the treatment of several malignancies, including breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma and squamous cell carcinoma of the head and neck.
Polaris medical affairs executive vice president John Bomalaski said ADI-PEG 20 is a promising cancer therapeutic not only as monotherapy but in combination therapy.
"We look forward to continuing clinical development in these and in other areas to understand the full potential for this therapeutic," Bomalaski added.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250